Patient characteristics
| ID . | Age, y . | Previous lines of therapy, n . | Previous exposure* . | BMPC at diagnosis, % . | MC, type . | Creatinine, mg/dL . | eGFR, mL/min per 1.73 m2 . | CKD stage . | Proteinuria, g/24 h . | dFLC, mg/L . | FLC κ/λ ratio . | Main side effect . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 69 | 5 | MDex, BDex, PDex, TDex, Be-P | 10 | IgGκ | 2.29 | 32 | 4 | 1.08 | 144 | 27.0 | — |
| 2 | 41 | 1 | CyBorD | 23 | LCκ | 4.03 | 15 | 4 | 0.77 | 52 | 2.01 | |
| 3 | 74 | 5 | MDex, BDex, LDex, PDex, Be-P | 30 | BJPκ | 2.00 | 32 | 3 | 1.56 | 2740 | 139 | Pneumonia |
| 4 | 66 | 5 | MDex, BDex, LDex | 10 | IgGκ | 1.56 | 34 | 3 | 1.83 | 174 | 8.5 | — |
| 5 | 59 | 1 | CyBorD | 12 | LCκ | 3.84 | 12 | 5 | 2.83 | 435 | 16.5 | Pneumonia |
| 6 | 55 | 4 | MDex, BDex, PDex | 15 | BJPκ | 2.37 | 30 | 3 | 1.86 | 247 | 25.2 | — |
| 7 | 64 | 1 | CyBorD | 13 | IgGκ | 2.37 | 21 | 4 | 0.51 | 1199 | 78.3 | — |
| 8 | 30 | 4 | MDex, BDex, TDex, PDex | 10 | BJPκ | 3.36 | 23 | 4 | 1.00 | 88 | 2.5 | — |
| ID . | Age, y . | Previous lines of therapy, n . | Previous exposure* . | BMPC at diagnosis, % . | MC, type . | Creatinine, mg/dL . | eGFR, mL/min per 1.73 m2 . | CKD stage . | Proteinuria, g/24 h . | dFLC, mg/L . | FLC κ/λ ratio . | Main side effect . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 69 | 5 | MDex, BDex, PDex, TDex, Be-P | 10 | IgGκ | 2.29 | 32 | 4 | 1.08 | 144 | 27.0 | — |
| 2 | 41 | 1 | CyBorD | 23 | LCκ | 4.03 | 15 | 4 | 0.77 | 52 | 2.01 | |
| 3 | 74 | 5 | MDex, BDex, LDex, PDex, Be-P | 30 | BJPκ | 2.00 | 32 | 3 | 1.56 | 2740 | 139 | Pneumonia |
| 4 | 66 | 5 | MDex, BDex, LDex | 10 | IgGκ | 1.56 | 34 | 3 | 1.83 | 174 | 8.5 | — |
| 5 | 59 | 1 | CyBorD | 12 | LCκ | 3.84 | 12 | 5 | 2.83 | 435 | 16.5 | Pneumonia |
| 6 | 55 | 4 | MDex, BDex, PDex | 15 | BJPκ | 2.37 | 30 | 3 | 1.86 | 247 | 25.2 | — |
| 7 | 64 | 1 | CyBorD | 13 | IgGκ | 2.37 | 21 | 4 | 0.51 | 1199 | 78.3 | — |
| 8 | 30 | 4 | MDex, BDex, TDex, PDex | 10 | BJPκ | 3.36 | 23 | 4 | 1.00 | 88 | 2.5 | — |
—, no main side effect reported; BDex, bortezomib and dexamethasone; Be-P, bendamustine and prednisone; BJP, Bence Jones protein; BMPC, bone marrow plasma cell infiltrate; CKD, chronic kidney disease; CyBorD, cyclophosphamide, bortezomib and dexamethasone; IgG, immunoglobulin G; LC, light chain–only monoclonal protein; LDex, lenalidomide and dexamethasone; MC, monoclonal component; MDex, melphalan and dexamethasone; PDex, pomalidomide and dexamethasone; TDex, thalidomide and dexamethasone.
Treatment regimens are reported in order of use. Patients 2, 5, and 7 received daratumumab, bortezomib, and dexamethasone.